# 177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-risk Neuroblastoma

> **NCT04903899** · PHASE2 · RECRUITING · sponsor: **Jakob Stenman** · enrollment: 24 (estimated)

## Conditions studied

- Neuroblastoma Recurrent
- Neuroblastoma

## Interventions

- **COMBINATION_PRODUCT:** 177Lu-DOTATATE

## Key facts

- **NCT ID:** NCT04903899
- **Lead sponsor:** Jakob Stenman
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-05-19
- **Primary completion:** 2026-05-20
- **Final completion:** 2031-05-20
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2025-02-11

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04903899

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04903899, "177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-risk Neuroblastoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04903899. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*